|Re: Dr. Yingling joins BIND from Bristol-Myers Squibb (BMS), where he was vice pr...|
What's the next potential catalyst for a boom? Haven't been in this for a while, always liked the potential, but have not been following. What's with the low price?
Share This Post:
My postings are not investment advice or investment solicitation. I am not a registered investment advisor or broker dealer. All of my thoughts are opinions and intended for educational purposes only and I am not reliable for any potential damages that may be incurred from reliance on this information. I do not guarantee or make claims to the accuracy or completeness of anything I post. I may buy, sell, or short any securities/options that I mention at anytime, even prior to posting,with no warning. Individuals should perform their own due diligence before investing in any stock at anytime and not base any decisions on my postings or by other individuals. Individuals should assume 100% responsibility for their own investing.
| Reply to singhtelecom - Msg #588 - 02/09/2017 15:25|
Dr. Yingling joins BIND from Bristol-Myers Squibb (BMS), where he was vice president, Oncology Discovery and Translational Research. During his tenure at BMS, he was responsible for the oncology research portfolio as well as translational capabilities in oncology and immunoscience, contributing to the discovery and development of potentially transformative medicines in immuno-oncology. He championed several small molecule drug discovery programs including IDO (indoleamine-2,3 dioxygenase), TGF-β and other important intracellular tumor cell targets. He also expanded the biologics portfolio with the addition of FS102, a novel anti-HER2 monoclonal antibody, and several proprietary antibody drug conjugate assets.
Dr. Yingling began his pharmaceutical career as a senior biologist in oncology at Eli Lilly & Company in 2000. During his 13-year tenure, he served in various positions of increasing responsibility including CSO of Angiogenesis & Tumor Microenvironment Biology, Vice President of Oncology Research and Vice President of Translational Science and Technology. In those roles, he led innovative drug discovery programs focused on the tumor microenvironment, contributed to the expansion of Lilly’s oncology portfolio into targeted therapy and biologics culminating in the acquisition of ImClone in 2008 and integrated tailored therapeutic capabilities across Lilly Research Laboratories. As vice president of Translational Science and Technology, he led target enablement and screening, structural biology, fragment-based drug design and lead optimization biology capabilities across multiple therapeutic areas. Dr. Yingling earned his Ph.D. in Cell and Molecular Biology and Pharmacology at Duke University and was a Howard Hughes Postdoctoral Fellow at Vanderbilt University.